Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases.  Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a T1/2 life extending tissue targeting, non-immunogenic scFv technology.

Viva BioInnovator

Echo Investment Capital

Alexandria Venture Investments

Leaps by Bayer

Lumira Ventures

Plains Ventures

Amana Investments

ATEM Capital

MPM Capital

John Mumm

Deka Biosciences, Inc

Google

Google Cloud

Chief Operations Officer

John Conner

Program and Project Management

Allison Long

Business Management

Clayton Costa

Operations

Dave Boclair

Research Director

Jeffrey Stinson

Senior Manager

Yuanyuan Wang

Engineering

Alice Hsu

Benjamin George

Legal

Christopher Yaen

David Langan

Allan Gobbs

Detlev Biniszkiewicz

Co-Founder, Chief Executive Officer

Pavel Khrimian

Co-Founder & CBO

Keith-Harrison Dewedoff

Chief Financial Officer

Washington DC Metro Area Companies With More Than $1M in Revenue (Top 10K)

Germantown Companies

Washington DC Metro Area Companies With Less Than $500M in Revenue (Top 10K)

Biotechnology Companies With Fewer Than 50 Employees (Top 10K)

Early stage biotechnology start-up developing next generation cytokine therapeutics

Venture Round - Deka Biosciences

Series B - Deka Biosciences

Series A - Deka Biosciences

Germantown

Maryland

United States

North America

Deka Biosciences

Deka Biosciences, Inc on LinkedIn: Our CBO, Pavel Khrimian is currently attending the US Pharma and Biotech…

Deka Biosciences, Inc on LinkedIn: Deka Employee Spotlight: Javier Goitia Javier is a Research Associate at…

Deka Biosciences, Inc on LinkedIn: We are pleased to welcome Dr. Abhishek Tripathi to our Scientific Advisory…

Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors

Dual cytokine fusion proteins comprising il-10

Big biotech and a mapping megaround: Here are DC’s top ...

A cytokine therapy platform designed to treat cancer and inflammatory diseases by combining cytokines in a single treatment to target the immune system.

Involves disease-targeting scaffolds that link cytokines to stimulate the immune system against cancer cells.

Combines anti-inflammatory cytokines targeted to specific tissue markers for treating inflammatory diseases.

Utilizes genetic tests to predict patient immune responses to different Diakines™, enabling personalized treatment.

Features a unique scaffold providing stability for higher manufacturing yields and lower costs.

Philippines

Asia

India

El Salvador

Canada

Moderna is a biotechnology company focused on developing mRNA-based vaccines and therapeutics.

Moderna

Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.

Incyte

HeioThera is a company focused on developing therapies for specific diseases, including autoimmune conditions.

HeioThera

Simcha Therapeutics is a biotechnology company focused on developing novel treatments for cancer and inflammatory diseases.

Simcha Therapeutics

Ankyra is a biopharmaceutical company developing advanced biopharmaceutical products for treating cancers and autoimmune diseases.

Ankyra

Deka Biosciences is a biotechnology company focused on the development of novel immunotherapies to treat cancer and autoimmune diseases. The company leverages its proprietary technology platforms to create transformative treatments that aim to improve patient outcomes.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 16, 2024 5:54 AM	412622b9
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Dec 4, 2024 8:54 AM	1450848a
crunchbase profile	general	Dec 4, 2024 12:40 PM	f1183edd
li profile	general	May 16, 2024 5:54 AM	8cce7db6
translate crunchbase fundingrounds	general	Dec 4, 2024 1:36 PM	2793006c
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:DEKABIOSCIENCES

Deka Biosciences